Updated November 2021 DGL bulletin data
—
In November, for the whole market, Keytruda still remains in the first place in the ranking. Interestingly, NHF spending on its reimbursement increased by 81.0% compared to 2020, with cumulative reimbursement value from January to November 2021 of 253 million, while the total amount of reimbursement for 2020 was 172 million. The increase may be related to the extension of registration for Keytruda with two new indications (treatment of lung cancer and melanoma) in January 2021.
More data in our IDA TOP10 report: https://lnkd.in/eVe9keS